| Identification | Back Directory | [Name]
ZG-2291 | [CAS]
2962103-40-6 | [Synonyms]
ZG-2291
Glycine, N-[[5-[3-(3-chlorophenyl)-5-isoxazolyl]-3-hydroxy-2-pyridinyl]carbonyl]- | [Molecular Formula]
C17H12ClN3O5 | [MOL File]
2962103-40-6.mol | [Molecular Weight]
373.75 |
| Chemical Properties | Back Directory | [Boiling point ]
777.8±60.0 °C(predicted) | [density ]
1.488±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
3.25±0.10(predicted) |
| Hazard Information | Back Directory | [Uses]
ZG-2291 is a selective inhibitor targeting FIH (Factor Inhibiting HIF) with oral activity. By binding to FIH, ZG-2291 promotes a conformational flip of a catalytically important tyrosine, enabling selective inhibition of FIH without affecting other 2OG oxygenases in the JmjC subfamily. ZG-2291k enhances thermogenesis in ob/ob mice and improves obesity-related symptoms and metabolic dysfunctions. ZG-2291 holds promise for research in the field of obesity-related diseases[1]. | [in vivo]
ZG-2291 (10 mg/kg, i.p., every other day for 30 days) protects against the
effects of obesity and notably improves obesity-associated
metabolic dysfunction in ob/ob mice[1]. | Animal Model: | ob/ob
mice | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), every other day for a total of 30 days | | Result: | Resulted in lower body weight, reduced hepatic TG/TC, and lower serum TG/TC/low-density lipoprotein (LDL) cholesterol levels in mice compared to the control group |
| [References]
[1] Wu Y, et al. A Small-Molecule Inhibitor of Factor Inhibiting HIF Binding to a Tyrosine-flip Pocket for the Treatment of Obesity. Angew Chem Int Ed Engl. 2024 Jun 26:e202410438. DOI:10.1002/anie.202410438 |
|
|